Bayer acquires BlueRock Therapeutics to build leading position in cell therapy

Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRock Therapeutics to continue to operate as an independent company
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news